Dupixent and Narrowband UVB for Atopic Dermatitis

Part of paid clinical trials in East Windsor, New Jersey.

Sponsor
Psoriasis Treatment Center of Central New Jersey
Study ID
NCT05285839
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dupixent — DRUG
    dupilumab 300mg

Study Details

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Key Dates

Start date
Apr 19, 2022
Status verified
Mar 2024
Primary completion
Dec 1, 2024
Completion
Dec 15, 2024

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dupixent and Narrowband UVB
    Dupixent and Narrowband UVB

Primary Outcome Measure

Investigators Global Assessment Score of score of 0 or 1 [ Time Frame: 12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Eczema Treatment Center of New JerseyEast WindsorNew Jersey08520
Elise Nelson
[email protected]
609-443-4500
Jerry Bagel, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in East Windsor, NJ

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Eczema Treatment Center of New Jersey· East Windsor, NJ

Related Studies